NYSE:NVO - New York Stock Exchange, Inc. - US6701002056 - ADR - Currency: USD
58.08
-4.8 (-7.63%)
The current stock price of NVO is 58.08 USD. In the past month the price decreased by -26.29%. In the past year, price decreased by -52.67%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 64.61 | 796.27B | ||
JNJ | JOHNSON & JOHNSON | 15.67 | 379.48B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.96 | 218.96B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 16.29 | 209.55B | ||
MRK | MERCK & CO. INC. | 10.21 | 196.28B | ||
PFE | PFIZER INC | 7.12 | 125.57B | ||
SNY | SANOFI-ADR | 11.41 | 124.61B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 43.18 | 100.17B | ||
GSK | GSK PLC-SPON ADR | 8.3 | 72.81B | ||
ZTS | ZOETIS INC | 25.11 | 66.32B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.98 | 46.30B | ||
HLN | HALEON PLC-ADR | 21.29 | 46.11B |
Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
NOVO-NORDISK A/S-SPONS ADR
Novo Alle 1
Bagsvaerd 2880 DK
CEO: Lars Fruergaard Jorgensen
Employees: 69260
Company Website: https://www.novonordisk.com/
Investor Relations: https://www.novonordisk.com/investors.html
Phone: 4544448888
The current stock price of NVO is 58.08 USD. The price decreased by -7.63% in the last trading session.
The exchange symbol of NOVO-NORDISK A/S-SPONS ADR is NVO and it is listed on the New York Stock Exchange, Inc. exchange.
NVO stock is listed on the New York Stock Exchange, Inc. exchange.
32 analysts have analysed NVO and the average price target is 119.67 USD. This implies a price increase of 106.05% is expected in the next year compared to the current price of 58.08. Check the NOVO-NORDISK A/S-SPONS ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NOVO-NORDISK A/S-SPONS ADR (NVO) has a market capitalization of 257.82B USD. This makes NVO a Mega Cap stock.
NOVO-NORDISK A/S-SPONS ADR (NVO) currently has 69260 employees.
NOVO-NORDISK A/S-SPONS ADR (NVO) has a resistance level at 63.03. Check the full technical report for a detailed analysis of NVO support and resistance levels.
The Revenue of NOVO-NORDISK A/S-SPONS ADR (NVO) is expected to grow by 23.4% in the next year. Check the estimates tab for more information on the NVO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NOVO-NORDISK A/S-SPONS ADR (NVO) has a dividend yield of 2.71%. The yearly dividend amount is currently 1.51. Check the full fundamental report for a detailed analysis of NVO dividend history, reliability and sustainability.
NOVO-NORDISK A/S-SPONS ADR (NVO) will report earnings on 2025-05-07, before the market open.
The PE ratio for NOVO-NORDISK A/S-SPONS ADR (NVO) is 16.83. This is based on the reported non-GAAP earnings per share of 3.45 and the current share price of 58.08 USD. Check the full fundamental report for a full analysis of the valuation metrics for NVO.
The outstanding short interest for NOVO-NORDISK A/S-SPONS ADR (NVO) is 0.31% of its float. Check the ownership tab for more information on the NVO short interest.
ChartMill assigns a fundamental rating of 8 / 10 to NVO. Both the health and profitability get an excellent rating, making NVO a very profitable company, without any liquidiy or solvency issues.
Over the last trailing twelve months NVO reported a non-GAAP Earnings per Share(EPS) of 3.45. The EPS increased by 21.57% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 34.78% | ||
ROA | 21.68% | ||
ROE | 70.38% | ||
Debt/Equity | 0.62 |
ChartMill assigns a Buy % Consensus number of 77% to NVO. The Buy consensus is the average rating of analysts ratings from 32 analysts.
For the next year, analysts expect an EPS growth of 19.72% and a revenue growth 23.4% for NVO